J. Kumar

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus

V. Mathur, H. Hait, P. Crawford, 2017, American Journal of Nephrology.

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

P. Gosse, S. Oparil, Pankaj Gupta, 2022, The Lancet.

Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients

F. Menzaghi, R. Spencer, M. Kashif, 2020, Kidney international reports.

A US trial to compare the efficacy , safety and immunogenicity of subcutaneous HX 575 ( proposed biosimilar epoetin alfa ) with the reference medicine in the treatment of anemia associated with chronic kidney disease

J. Fink, M. Weir, R. Agarwal, 2018 .

A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease

Ajay K. Singh, J. Fink, M. Weir, 2017, American Journal of Nephrology.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Debra F. Weinstein, Michael G. Miller, M. A. Ferreira, 2019, Lancet.